Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.

Daniel-Wayman S, Abate G, Barber DL, Bermudez LE, Coler RN, Cynamon MH, Daley CL, Davidson RM, Dick T, Floto RA, Henkle E, Holland SM, Jackson M, Lee RE, Nuermberger EL, Olivier KN, Ordway DJ, Prevots DR, Sacchettini JC, Salfinger M, Sassetti CM, Sizemore CF, Winthrop KL, Zelazny AM.

Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP. No abstract available.

PMID:
30428263
2.

Therapy for Mycobacterium kansasii Infection: Beyond 2018.

DeStefano MS, Shoen CM, Cynamon MH.

Front Microbiol. 2018 Sep 24;9:2271. doi: 10.3389/fmicb.2018.02271. eCollection 2018.

3.

Modeling the HIV-1 Antiretroviral Therapeutic Drug Interaction.

Cynamon MH, Damianopoulos EN.

AIDS Res Hum Retroviruses. 2018 Aug 3. doi: 10.1089/AID.2018.0113. [Epub ahead of print]

PMID:
30073843
4.

2-N-Arylthiazole inhibitors of Mycobacterium tuberculosis.

Clark MP, Wang T, Perola E, Deininger DD, Zuccola HJ, Jones SM, Gao H, VanderVen BC, Russell DG, Shoen CM, Cynamon MH, Thomson JA, Locher CP.

Bioorg Med Chem Lett. 2017 Sep 1;27(17):3987-3991. doi: 10.1016/j.bmcl.2017.07.067. Epub 2017 Jul 27.

PMID:
28778468
5.

The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.

Grossman TH, Shoen CM, Jones SM, Jones PL, Cynamon MH, Locher CP.

Antimicrob Agents Chemother. 2015 Mar;59(3):1534-41. doi: 10.1128/AAC.04271-14. Epub 2014 Dec 22.

6.

A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections.

Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, Ngwane AH, Wiid IJ, van Helden PD, Betoudji F, Nuermberger EL, Thomson JA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. doi: 10.1128/AAC.04347-14. Epub 2014 Dec 22.

7.

Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones.

Lee Y, Mootien S, Shoen C, Destefano M, Cirillo P, Asojo OA, Yeung KR, Ledizet M, Cynamon MH, Aristoff PA, Koski RA, Kaplan PA, Anthony KG.

Biochem Pharmacol. 2013 Jul 15;86(2):222-30. doi: 10.1016/j.bcp.2013.05.004. Epub 2013 May 13.

8.

A Modified Bacillus Calmette-Guérin (BCG) Vaccine with Reduced Activity of Antioxidants and Glutamine Synthetase Exhibits Enhanced Protection of Mice despite Diminished in Vivo Persistence.

Shoen CM, DeStefano MS, Hager CC, Tham KT, Braunstein M, Allen AD, Gates HO, Cynamon MH, Kernodle DS.

Vaccines (Basel). 2013 Jan 11;1(1):34-57. doi: 10.3390/vaccines1010034.

9.

Thiadiazolidinones: a new class of alanine racemase inhibitors with antimicrobial activity against methicillin-resistant Staphylococcus aureus.

Ciustea M, Mootien S, Rosato AE, Perez O, Cirillo P, Yeung KR, Ledizet M, Cynamon MH, Aristoff PA, Koski RA, Kaplan PA, Anthony KG.

Biochem Pharmacol. 2012 Feb 1;83(3):368-77. doi: 10.1016/j.bcp.2011.11.021. Epub 2011 Nov 29.

10.

Effects of opsonization of Rhodococcus equi on bacterial viability and phagocyte activation.

Dawson DR, Nydam DV, Price CT, Graham JE, Cynamon MH, Divers TJ, Felippe MJ.

Am J Vet Res. 2011 Nov;72(11):1465-75. doi: 10.2460/ajvr.72.11.1465.

PMID:
22023124
11.

New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis.

Anthony KG, Strych U, Yeung KR, Shoen CS, Perez O, Krause KL, Cynamon MH, Aristoff PA, Koski RA.

PLoS One. 2011;6(5):e20374. doi: 10.1371/journal.pone.0020374. Epub 2011 May 26.

12.

In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.

Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH.

Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80. doi: 10.1128/AAC.00287-10. Epub 2010 Jun 1.

13.

The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.

Mendez S, Traslavina R, Hinchman M, Huang L, Green P, Cynamon MH, Welch JT.

Antimicrob Agents Chemother. 2009 Dec;53(12):5114-21. doi: 10.1128/AAC.01146-09. Epub 2009 Sep 21.

14.

Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Hearn MJ, Cynamon MH, Chen MF, Coppins R, Davis J, Joo-On Kang H, Noble A, Tu-Sekine B, Terrot MS, Trombino D, Thai M, Webster ER, Wilson R.

Eur J Med Chem. 2009 Oct;44(10):4169-78. doi: 10.1016/j.ejmech.2009.05.009. Epub 2009 May 21.

15.

Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs.

Chung WJ, Kornilov A, Brodsky BH, Higgins M, Sanchez T, Heifets LB, Cynamon MH, Welch J.

Tuberculosis (Edinb). 2008 Sep;88(5):410-9. doi: 10.1016/j.tube.2008.06.001.

PMID:
18674969
16.
17.

The activity of grepafloxacin in two murine models of Mycobacterium avium infection.

Cynamon MH, Sklaney M, Yeo AE.

J Infect Chemother. 2004 Jun;10(3):185-8.

PMID:
15290460
18.

Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.

Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH.

Scand J Infect Dis. 2004;36(2):150-4.

PMID:
15061673
19.

Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.

Shoen CM, DeStefano MS, Sklaney MR, Monica BJ, Slee AM, Cynamon MH.

J Antimicrob Chemother. 2004 Apr;53(4):641-5. Epub 2004 Feb 18.

PMID:
14973154
20.

Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base.

Hearn MJ, Cynamon MH.

J Antimicrob Chemother. 2004 Feb;53(2):185-91. Epub 2003 Dec 19.

PMID:
14688045
21.

BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis.

Cynamon MH, Alvirez-Freites E, Yeo AE.

J Antimicrob Chemother. 2004 Feb;53(2):403-5. Epub 2003 Dec 19. No abstract available.

PMID:
14688038
22.

In vitro susceptibility of nocardia species to cethromycin, clarithromycin and amikacin.

Alvirez-Freites E, Yeo AE, DeStefano MS, Cynamon MH.

Eur J Clin Microbiol Infect Dis. 2004 Jan;23(1):69-70. Epub 2003 Dec 10. No abstract available.

PMID:
14666401
23.

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.

Cynamon MH, Sklaney M.

Antimicrob Agents Chemother. 2003 Aug;47(8):2442-4.

24.
25.

Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection.

Cynamon MH, Elliott SA, DeStefano MS, Yeo AE.

J Antimicrob Chemother. 2003 Aug;52(2):306-7. Epub 2003 Jul 1.

PMID:
12837729
26.
28.

Enhanced in vitro activity of dihydrofolate reductase and dihydropteroase synthase inhibitors in combination against Nocardia spp.

Thielking DM, Destefano MS, Cynamon MH, Yeo AE.

Antimicrob Agents Chemother. 2003 Mar;47(3):1174. No abstract available.

29.

Development potential of rifalazil.

Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI.

Expert Opin Investig Drugs. 2003 Feb;12(2):255-71. Review.

PMID:
12556219
30.

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Alvirez-Freites EJ, Carter JL, Cynamon MH.

Antimicrob Agents Chemother. 2002 Apr;46(4):1022-5.

31.

Iron-cofactored superoxide dismutase inhibits host responses to Mycobacterium tuberculosis.

Edwards KM, Cynamon MH, Voladri RK, Hager CC, DeStefano MS, Tham KT, Lakey DL, Bochan MR, Kernodle DS.

Am J Respir Crit Care Med. 2001 Dec 15;164(12):2213-9.

PMID:
11751190
32.
33.

Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model.

Cynamon MH, Carter JL, Shoen CM.

Antimicrob Agents Chemother. 2000 Oct;44(10):2895-6.

34.
35.

Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice.

Shoen CM, Chase SE, DeStefano MS, Harpster TS, Chmielewski AJ, Cynamon MH.

Antimicrob Agents Chemother. 2000 Jun;44(6):1458-62.

36.

High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.

Cynamon MH, Zhang Y, Harpster T, Cheng S, DeStefano MS.

Antimicrob Agents Chemother. 1999 Dec;43(12):2922-4.

37.

Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.

Koletar SL, Berry AJ, Cynamon MH, Jacobson J, Currier JS, MacGregor RR, Dunne MW, Williams DJ.

Antimicrob Agents Chemother. 1999 Dec;43(12):2869-72.

38.

Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.

Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH.

Antimicrob Agents Chemother. 1999 Oct;43(10):2356-60.

39.

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Cynamon MH, Klemens SP, Sharpe CA, Chase S.

Antimicrob Agents Chemother. 1999 May;43(5):1189-91.

40.

In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex.

Shoen CM, Choromanska O, Reynolds RC, Piper JR, Johnson CA, Cynamon MH.

Antimicrob Agents Chemother. 1998 Dec;42(12):3315-6.

41.

In vitro antimycobacterial activity of 5-chloropyrazinamide.

Cynamon MH, Speirs RJ, Welch JT.

Antimicrob Agents Chemother. 1998 Feb;42(2):462-3.

42.

Photo quiz. Tinea barbae caused by Trichophyton verrucosum.

Kiska DL, Cynamon MH.

Clin Infect Dis. 1997 Oct;25(4):805, 871. No abstract available.

PMID:
9410095
43.

Genome and MIC stability in Mycobacterium tuberculosis and indications for continuation of use of isoniazid in multidrug-resistant tuberculosis.

Victor TC, Warren R, Butt JL, Jordaan AM, Felix JV, Venter A, Sirgel FA, Schaaf HS, Donald PR, Richardson M, Cynamon MH, Van Helden PD.

J Med Microbiol. 1997 Oct;46(10):847-57.

PMID:
9364141
44.

Enhanced in vitro activity of WR99210 in combination with dapsone against Mycobacterium avium complex.

Shah LM, DeStefano MS, Cynamon MH.

Antimicrob Agents Chemother. 1996 Nov;40(11):2644-5.

45.

Enhanced in vitro activity of pyrimethamine in combination with dapsone against Mycobacterium avium complex.

Shah LM, Meyer SC, Cynamon MH.

Antimicrob Agents Chemother. 1996 Oct;40(10):2426-7.

46.

Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.

Bergmann KE, Cynamon MH, Welch JT.

J Med Chem. 1996 Aug 16;39(17):3394-400.

PMID:
8765523
47.

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.

Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE.

J Med Chem. 1996 Feb 2;39(3):680-5.

PMID:
8576910
48.
49.
50.

Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.

Cynamon MH, Gimi R, Gyenes F, Sharpe CA, Bergmann KE, Han HJ, Gregor LB, Rapolu R, Luciano G, Welch JT.

J Med Chem. 1995 Sep 29;38(20):3902-7.

PMID:
7562923

Supplemental Content

Loading ...
Support Center